Biotech · Private company
Xcovery Holdings, Inc.
Track this companyFree. Adds Xcovery Holdings, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials82 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- crizotinibPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- X-396 (ensartinib)Phase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Phase I: X-396 (ensartinib)Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Phase II: X-396 (ensartinib)Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Ensartinib HydrochloridePhase 1 · BioequivalencyClinicalTrials.gov · fetched Nov 12, 2026
- EnsartinibNon-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted ConditionsPHASE1 · COMPLETED · started Nov 29, 2022ClinicalTrials.gov NCT05665283 · fetched Nov 12, 2026
- Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPHASE2 · TERMINATED · started Oct 7, 2020ClinicalTrials.gov NCT04373369 · fetched Nov 12, 2026
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsPHASE1_PHASE2 · COMPLETED · started Jul 10, 2018ClinicalTrials.gov NCT03583086 · fetched Nov 12, 2026
- Treating Patients With Melanoma and ALK Alterations With EnsartinibPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 10, 2018ClinicalTrials.gov NCT03420508 · fetched Nov 12, 2026
- Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerPHASE1_PHASE2 · COMPLETED · started May 10, 2017ClinicalTrials.gov NCT02898116 · fetched Nov 12, 2026
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 1, 2016ClinicalTrials.gov NCT02767804 · fetched Nov 12, 2026
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerPHASE1_PHASE2 · COMPLETED · started Jun 1, 2012ClinicalTrials.gov NCT01625234 · fetched Nov 12, 2026
- Expanded Access to Ensartinib for Participants With ALK+ NSCLCAVAILABLEClinicalTrials.gov NCT04146571 · fetched Nov 12, 2026